Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer.
Larkina M, Plotnikov E, Bezverkhniaia E, Shabanova Y, Tretyakova M, Yuldasheva F, Zelchan R, Schulga A, Konovalova E, Vorobyeva A, Garousi J, Gräslund T, Belousov M, Tolmachev V, Deyev S. Larkina M, et al. Int J Mol Sci. 2022 Nov 3;23(21):13443. doi: 10.3390/ijms232113443. Int J Mol Sci. 2022. PMID: 36362226 Free PMC article.
Synthesis, 123I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures.
Hasnowo LA, Larkina MS, Plotnikov E, Bodenko V, Yuldasheva F, Stasyuk E, Petrov SA, Zyk NY, Machulkin AE, Vorozhtsov NI, Beloglazkina EK, Nenajdenko VG, Tolmachev V, Orlova A, Majouga AG, Yusubov MS. Hasnowo LA, et al. Int J Mol Sci. 2023 Jul 30;24(15):12206. doi: 10.3390/ijms241512206. Int J Mol Sci. 2023. PMID: 37569582 Free PMC article.
Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins G3 for the 99mTc-Based Imaging of HER2-Expressing Malignant Tumors.
Larkina M, Varvashenya R, Yuldasheva F, Plotnikov E, Bezverkhniaia E, Tretyakova M, Zelchan R, Schulga A, Konovalova E, Vorobyeva A, Belousov M, Orlova A, Tolmachev V, Deyev S. Larkina M, et al. Mol Pharm. 2024 Apr 1;21(4):1919-1932. doi: 10.1021/acs.molpharmaceut.3c01173. Mol Pharm. 2024. PMID: 38557163
Half-life extension via ADB-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
Zhang J, Bodenko V, Larkina M, Bezverkhniaia E, Xu T, Liao Y, Abouzayed A, Plotnikov E, Tretyakova M, Yuldasheva F, Belousov MV, Orlova A, Tolmachev V, Gräslund T, Vorobyeva A. Zhang J, et al. J Control Release. 2024 Apr 30:S0168-3659(24)00280-3. doi: 10.1016/j.jconrel.2024.04.051. Online ahead of print. J Control Release. 2024. PMID: 38697314
49 results